Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Treatment For Receding Gums: No Pain, Lots Of Gain
Tufts dental researchers conducted a three-year follow-up study that examined the stability of a treatment option for receding gums and found that complete root coverage the goal of the surgery had been maintained. This specific tissue regeneration application, developed at Tufts, reduces the considerable pain and recovery time of gum grafting surgery. The case study of six patients is published in the July 2009 issue of the Journal of Periodontology.

UK Court Of Appeal Rules In Smith & Nephew's Favour
Smith & Nephew"s Advanced Wound Management division (NYSE:SNN) announced that the UK Court of Appeal has ruled as invalid all claims asserted against Smith and Nephew of the patent EP 0 626 720 that is licensed to Kinetic Concepts, Inc. (NYSE: KCI). As a result, the preliminary injunction against Smith & Nephew"s RENASYS(TM)-F NPWT system has been lifted.
News of the day
Study Finds Noninvasive Blood Test For Liver Fibrosis May Alleviate Need For Liver Biopsies For Some Patients With Chronic Hepatitis C
A study in the June issue of Clinical Gastroenterology and Hepatology, published by Elsevier, demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel may help physicians more accurately diagnose and stage liver fibrosis in patients with chronic hepatitis C (HCV), potentially alleviating the need for liver biopsy, the standard of care for staging fibrosis, in a particular subset of patients. The Hepascore test panel is provided exclusively by Quest Diagnostics Incorporated (NYSE: DGX), the world"s leading provider of diagnostic testing, information and services.
Diagnostics

Small Clinical Trial Examines Drug's Ability To Reduce HIV In Body

In the first human trial of GlaxoSmithKline"s (GSK) experimental HIV drug S/GSK1349572, the drug was able to reduce HIV to undetectable levels in 70 percent of the 35 patients taking the treatment for 10 days, according to findings presented at the International AIDS Society"s conference in Cape Town, South Africa, Bloomberg reports. The drug decreased the virus in the body "without the signs of resistance linked to treatments from" Merck"s Isentress and Gilead Sciences" Elvitegravir, according to Bloomberg. GSK will begin a larger trial of the drug this month, Sherene Min, the director of clinical pharmacology discovery medicine for GSK, said. Michael Saag, director of the Center for AIDS Research at the University of Alabama, who is not affiliated with the study, said the scale of viral reduction was "spectacular," adding, "In 10 days to go to undetectable is pretty strong. This thing"s working" (Bennett, 7/21). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009